Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oliceridine vs sufentanil for prophylactic analgesia in gynecologic laparoscopic surgery
ChiCTR2400092891Phase 4Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Shantou University Medical College
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of oliceridine in gynecologic tumor (2 arms), sponsored by Affiliated Cancer Hospital of Shantou University Medical College. Primary endpoint: Area under the curve (AUC) of VAS pain score. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
oliceridine
03
Conditions
gynecologic tumor
Beyond the preview
Go deeper on ChiCTR2400092891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092891.